Trevena Announces Completion of Initial Analysis of OLINVYK Continuous Respiratory Monitoring Data From VOLITION Study and Presentation at American Society of Anesthesiologists Conference
Trevena Announces Completion of Initial Analysis of OLINVYK Continuous Respiratory Monitoring Data From VOLITION Study and Presentation at American Society of Anesthesiologists Conference
Trevena宣佈完成對來自VOLITION研究的OLINVYK持續呼吸監測數據的初步分析並在美國麻醉師學會會議上發表的演講
Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced completion of initial analysis of OLINVYK continuous respiratory monitoring data from the VOLITION study.
專注於為中樞神經系統疾病患者開發和商業化新藥的生物製藥公司特雷維納公司(納斯達克代碼：TRVN)今天宣佈，完成了對OLINVYK持續呼吸監測數據的初步分析。
The VOLITION study, a real-world, open-label, multi-site study, assessed the potential impact of OLINVYK on respiratory, gastrointestinal (GI), and cognitive function outcomes in the postoperative setting. The Company previously announced GI and cognition data from the study.
這項意志力研究是一項真實世界、開放標籤、多地點的研究，評估了OLINVYK對術後環境中呼吸、胃腸道(GI)和認知功能結果的潛在影響。該公司此前公佈了這項研究的GI和認知數據。